NASDAQ$CRSP
CRISPR Therapeutics AG · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2022.
CRISPR Therapeutics reported its Q3 2022 financial results, highlighting progress in its clinical pipeline, including exa-cel's regulatory submissions and advancements in immuno-oncology and regenerative medicine programs.
- Exa-cel submission to the FDA for rolling review expected to begin in November, with completion expected in Q1 2023.
- EMA and MHRA submissions for exa-cel are on track for Q4 2022.
- Enrollment and dosing are ongoing for CTX110 and CTX130, with additional data expected in 2022.
- IND cleared by the FDA for CTX112, and CTA cleared by Health Canada for VCTX211.
Headline financials
Revenue & EPS history
CRISPR Therapeutics · Revenue · Quarterly
$94K
Revenue by segment
CRISPR Therapeutics · $762K total across 1 segment · Q1 2022
- Grant Revenue$762K+126.1%100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+2.1%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+1.4%
Avg return
30 days after
48%
19 / 40 earnings
Positive
+22.8%
Q3 2019
Best reaction
-7.7%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.1% | +2.4% | +6.3% | |
| Q4 2025 | +1.2% | +10.0% | +0.9% | |
| Q3 2025 | -1.0% | -4.7% | +4.5% | |
| Q1 2025 | -0.1% | -3.2% | +7.2% | |
| Q4 2024 | -2.8% | -8.3% | -18.2% | |
| Q3 2024 | +0.3% | +2.0% | -2.1% | |
| Q2 2024 | -3.5% | -8.0% | -11.9% | |
| Q1 2024 | -3.6% | +0.2% | +4.2% | |
| Q4 2023 | +9.5% | +9.3% | -9.0% | |
| Q3 2023 | +14.9% | +4.3% | +39.5% | |
| Q2 2023 | +4.1% | -2.6% | +0.3% | |
| Q1 2023 | +13.7% | +14.5% | +12.5% | |
| Q4 2022 | -1.0% | -5.6% | -15.2% | |
| Q3 2022 | +4.5% | -2.2% | +3.8% | |
| Q2 2022 | -7.7% | -3.4% | -20.1% | |
| Q1 2022 | -1.5% | +8.8% | +53.8% | |
| Q4 2021 | +5.7% | -0.5% | +15.1% | |
| Q3 2021 | -3.0% | -1.8% | -26.9% | |
| Q2 2021 | +1.1% | +1.4% | +3.4% | |
| Q1 2021 | -0.1% | -3.3% | -12.8% | |
| Q4 2020 | -6.8% | -7.5% | -23.3% | |
| Q3 2020 | -1.8% | -12.2% | +23.9% | |
| Q2 2020 | -4.4% | -5.4% | -1.6% | |
| Q1 2020 | -5.5% | -11.9% | +13.3% | |
| Q4 2019 | +2.0% | -2.1% | -34.0% | |
| Q3 2019 | +22.8% | +27.7% | +70.9% | |
| Q2 2019 | -2.3% | -3.9% | -11.2% | |
| Q1 2019 | -2.0% | -1.1% | -10.1% | |
| Q4 2018 | +14.3% | +26.2% | +8.0% | |
| Q3 2018 | +7.5% | +3.2% | +0.0% | |
| Q2 2018 | -2.7% | -2.7% | +3.0% | |
| Q1 2018 | -0.4% | +2.0% | +29.6% | |
| Q4 2017 | +10.2% | +9.7% | -16.0% | |
| Q3 2017 | -6.5% | -2.1% | +4.1% | |
| Q2 2016 | +9.4% | +10.1% | +6.7% | |
| Q2 2017 | +9.4% | +10.1% | +6.7% | |
| Q1 2016 | -0.1% | -2.9% | -14.2% | |
| Q1 2017 | +4.3% | -4.2% | -17.9% | |
| Q4 2016 | +11.1% | +13.3% | -12.4% | |
| Q3 2016 | -7.0% | -1.9% | -3.3% | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro